Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target
Lead Product(s) : RL-007
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : RL-007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cognitive Dysfunction-associated with Schizophrenia.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 17, 2023
Lead Product(s) : RL-007
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety, Biomarker Study of RL-007 in Subjects With Schizophrenia
Details : RL-007 is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Cognitive Dysfunction.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 30, 2021
Lead Product(s) : RL-007
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Details : Recognify's lead compound, "RL-007", previously called FSV7-007, has exhibited a modulating effect on three mechanisms that are central to learning and memory: the cholinergic, NMDA and GABA type B receptor systems.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Undisclosed
January 12, 2021
Lead Product(s) : RL-007
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : ATAI Life Sciences
Deal Size : Undisclosed
Deal Type : Acquisition
Reset All
